This content is machine translated Axial spondyloarthritis and psoriatic arthritis Effective and efficient against pain The anti-IL-17A monoclonal antibody ixekizumab has already been approved since 2016 for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. In 2020, axial spondyloarthritis (axSpA) was added… CME-Test
View Post 4 min This content is machine translated Rheumatoid arthritis Translational medicine and omics analyses: focus on proven and new therapeutic approaches In rheumatoid arthritis, the immune system attacks the synovial membrane of the synovium. If left untreated, there is a risk of gradual joint destruction. DMARDs are therefore used in severe…
View Post 11 min This content is machine translated Therapy of rheumatoid arthritis Long-term safety for RA patients under JAK inhibition The treatment of rheumatoid arthritis (RA) has made great progress over the past 20 years. This relates both to the range of drugs available and to developments in terms of… CME-Test
View Post 6 min This content is machine translated Valérie Krafft, Executive Director of the Rheumatism League Switzerland: “Rheumatic diseases still meet with a lot of misunderstanding from the public” The Swiss Rheumatism League has been working for people with rheumatism since 1958. In an interview, Executive Director Valérie Krafft explains how the non-profit organization supports those affected, why the…
View Post 4 min This content is machine translated Psoriatic arthritis (PsA) Guselkumab in joint involvement – successful interim results Long-term data from the pivotal DISCOVER-2 study show that treatment with guselkumab resulted in sustained improvements in joint and skin symptoms and functional capacity over a two-year period in biologic-naïve…
View Post 4 min This content is machine translated Personalized PsA therapy Psoriatic arthritis criterion-guided treatment An overarching principle for therapy selection in psoriatic arthritis is shared decision making with patients. The GRAPPA recommendations propose an individualized treatment approach that takes into account the predominant disease…
View Post 3 min This content is machine translated Psoriatic arthritis (PsoA) Pooled analysis on the efficacy of secukinumab from four phase III studies Improvement in clinical endpoints was seen with secukinumab treatment regardless of latency since initial psoriatic arthritis diagnosis, with patients diagnosed less than one year ago showing a slightly better response…
View Post 4 min This content is machine translated Systemic lupus erythematosus Innovative therapeutic approaches on the rise – pioneering new treatment strategies Systemic lupus erythematosus (SLE) carries a high risk of life-threatening organ damage, but there is new hope for sufferers. In recent years, the development of innovative treatment options has been…
View Post 3 min This content is machine translated Psoriasis: disease management during corona pandemic “Shared decision making” is especially important in these times Among psoriasis patients, there is often some uncertainty about the implications of their underlying disease and the respective system therapy with regard to the risk of a severe course of…
View Post 4 min This content is machine translated Comorbidity Research Psoriasis as a systemic disease – study findings on comorbid depression Psoriasis and psoriatic arthritis (PsoA) often have a significant impact on the daily life and quality of life of those affected. The prevalence of mental health comorbidities is increased, with…
View Post 5 min This content is machine translated Interview with Prof. Dr. med. Pascal Richette Facing the challenges of psoriatic arthritis management Despite remarkable progress in the treatment of patients with psoriatic arthritis (PsA), the management of this chronic disease still poses major challenges [1]. In the following interview, Prof. Pascal Richette,…
